Mesoblast limited (NASDAQ:MESO) – Equities research analysts at Oppenheimer cut their Q3 2018 earnings per share (EPS) estimates for Mesoblast in a research note issued on Wednesday. Oppenheimer analyst M. Breidenbach now expects that the company will earn ($0.20) per share for the quarter, down from their previous estimate of ($0.19). Oppenheimer has a “Buy” rating and a $16.00 price target on the stock. Oppenheimer also issued estimates for Mesoblast’s Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.45) EPS, Q1 2019 earnings at ($0.20) EPS, Q2 2019 earnings at ($0.21) EPS, Q3 2019 earnings at ($0.23) EPS and FY2019 earnings at ($0.59) EPS.

Other analysts also recently issued reports about the stock. Maxim Group set a $14.00 price target on shares of Mesoblast and gave the stock a “buy” rating in a report on Wednesday, November 15th. Cantor Fitzgerald set a $20.00 price target on shares of Mesoblast and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Saturday, January 13th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. Mesoblast presently has a consensus rating of “Hold” and a consensus target price of $13.54.

Shares of Mesoblast (NASDAQ:MESO) opened at $7.60 on Friday. Mesoblast has a twelve month low of $4.74 and a twelve month high of $12.50. The stock has a market cap of $706.60, a price-to-earnings ratio of -20.54 and a beta of 1.83.

An institutional investor recently bought a new position in Mesoblast stock. Penbrook Management LLC acquired a new stake in shares of Mesoblast limited (NASDAQ:MESO) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 266,800 shares of the company’s stock, valued at approximately $1,558,000. Mesoblast makes up about 1.4% of Penbrook Management LLC’s investment portfolio, making the stock its 18th largest holding. Penbrook Management LLC owned 0.28% of Mesoblast at the end of the most recent quarter. 2.74% of the stock is owned by institutional investors and hedge funds.

WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at

Mesoblast Company Profile

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with's FREE daily email newsletter.